Pharmaceutical Industry Residency Program

Pharmaceutical Industry Residency Program (PIRP)

The Pharmaceutical Industry Residency Program, formerly named the Industrial Pharmacy Residency Program, is administered by the Leslie Dan Faculty of Pharmacy, University of Toronto, in cooperation with participating Pharmaceutical Companies as listed below. These one or two year specialty residencies develop critical knowledge and skills and provide experience within the stated functional area. This is a national educational residency program for graduates from a recognized Pharmacy degree program; it is not an application for a position with a pharmaceutical company.

New this year

Over the last few years, many residents and company supervisors have communicated a desire to formally certify the program and we are excited to announce that we have successfully achieved program certification through the Leslie Dan Faculty of Pharmacy, University of Toronto. Current residents are eligible for the certificate provided they complete the requirements outlined in the terms of reference.

The Leslie Dan Faculty of Pharmacy will continue to support PIRP’s ability to provide high, quality, experiential learning through:

• Skills and educational webinars and exposure to pharmaceutical industry experts
• Resume and interview skills workshops
• Opportunity to network with PIRP residents and pharmaceutical industry professionals
• Participation in a new mentoring program with a PIRP graduate
• Collaboration with and guidance from University of Toronto faculty liaisons
• Coordination to address issues and ensure program requirements are met

PIRP Fees 

To help fund this program, starting in the 2024-25 cycle the program fees are as follows: 
Pharmaceutical company fees based on the number of residency positions offered: 

Applicant and resident non-refundable fees: 

• $250 at application (Oct 2023) 
• $2250 once successfully matched with a company (March 2024) 
• $2500 payable three months after residency employment starts (Q3-Q4 2024) 

Applications Process - Closed on Monday, October 2, 2023 at 5:00pm Eastern Time

Applications are now closed for Residencies occurring from September 2024 to August 2025. Applications for Residencies occurring from September 2025 to August 2026 will open in September 2024. If you have any questions about the application process, please contact: pharm.residency@utoronto.ca. 

Key Dates for 2024-25 Residency Application Cycle

The Product Development Regulatory and Annual Product Quality Review residencies with Roche, and the residencies with AstraZeneca will be 24 months in length. Please review the updated Terms of Reference document for more information.

2024-2025 Participating Companies

• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Eisai
• Gilead
• Lilly
• Medison
• Novo Nordisk
• Roche (Annual Product Quality Review, Medical Strategy and Product Development Regulatory)
• Sanofi